Abivax (France)

French clinical stage biotechnology company with its head office in Paris and research operations at Montpellier, founded in 2013 and listed in Paris and New York. Works on medicines that modulate the immune system through RNA biology, with obefazimod, an oral small molecule that enhances a microRNA involved in inflammation, in late stage trials for ulcerative colitis and Crohn's disease, and runs its own discovery chemistry, translational research and clinical development.